Liver transplantation in patients with hepatitis B virus infection: Outcome in asian versus white patients

Previous studies have found that Asian patients transplanted for hepatitis B virus (HBV) infection had worse outcomes than white patients. The aim of this study was to compare outcomes in Asian and white patients listed for liver transplantation for HBV infection. Data of all patients with HBV infection listed for liver transplantation between January 1996 and June 1998 from 20 centers in North America were collected using a survey. Total patients enrolled were 325 (171 whites, 126 Asians, 28 other races). There was no difference in demographics, liver biochemistry, and HBV replicative status between Asians and whites at the time of listing. More Asians had hepatocellular carcinoma and fewer Asians had hepatitis C or D virus coinfection. At the time of this survey, 70 Asians (55%) and 99 whites (58%) had been transplanted. Actuarial 2-year survival posttransplantation for Asians (88%) and whites (92%) was similar. Recurrent HBV infection occurred in 8 (11%) Asians and 12 (12%) whites. Five patients with recurrent HBV infection died, 4 of whom were Asian. Actuarial 2-year survival for Asians versus whites with recurrent HBV infection was 60% versus 90% (P =.04). In this large cohort of patients, overall survival and recurrent HBV infection posttransplantation were comparable between Asians and whites. However, Asians with recurrent HBV infection posttransplantation had significantly higher mortality.

[1]  J. Roberts,et al.  Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  P. Angus,et al.  Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  D. Pillay,et al.  High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. , 1999, Journal of hepatology.

[4]  J. Markmann,et al.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin , 1998, Hepatology.

[5]  E. Keeffe,et al.  Liver transplantation in Asian patients with chronic hepatitis B , 1997, Hepatology.

[6]  J. Roberts,et al.  Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin , 1996, Hepatology.

[7]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[8]  T. Pruett,et al.  Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. , 1996, Transplantation.

[9]  L. Ferrell,et al.  Hepatitis B and C coinfections and persistent hepatitis B infections: Clinical outcome and liver pathology after transplantation , 1996, Hepatology.

[10]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[11]  M. Rizzetto,et al.  Liver transplantation in carriers of the HBsAg. , 1991, Journal of hepatology.

[12]  D. V. van Thiel,et al.  Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease , 1991, Hepatology.

[13]  M. Moritz,et al.  Liver transplantation for chronic hepatitis B in Asian males. , 1993, Transplantation proceedings.